Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Immunocytochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- BAF1828 - Provider product page
- Provider
- R&D Systems
- Product name
- Human TREM2 Biotinylated Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human TREM2 in Western blots. In Western blots, less than 1% cross-reactivity with recombinant human (rh) TREM2b, rhTREM1, and recombinant mouse TREM3 is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Biotin
- Antigen sequence
Q9NZC2- Isotype
- IgG
- Vial size
- 50 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model.
Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma.
CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.
Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.
A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis.
A split-luciferase complementation, real-time reporting assay enables monitoring of the disease-associated transmembrane protein TREM2 in live cells.
Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X, Chen K, Wang N, Zhu L, Can D, Marten Y, Shinohara M, Liu CC, Du D, Sun H, Wen L, Xu H, Bu G, Chen XF
Nature communications 2019 Mar 25;10(1):1365
Nature communications 2019 Mar 25;10(1):1365
Exercise as a potential modulator of inflammation in patients with Alzheimer's disease measured in cerebrospinal fluid and plasma.
Jensen CS, Bahl JM, Østergaard LB, Høgh P, Wermuth L, Heslegrave A, Zetterberg H, Heegaard NHH, Hasselbalch SG, Simonsen AH
Experimental gerontology 2019 Jul 1;121:91-98
Experimental gerontology 2019 Jul 1;121:91-98
CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.
Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C, Dominantly Inherited Alzheimer Network, Alzheimer's Disease Neuroimaging Initiative
EMBO molecular medicine 2018 Dec;10(12)
EMBO molecular medicine 2018 Dec;10(12)
Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.
Woollacott IOC, Nicholas JM, Heslegrave A, Heller C, Foiani MS, Dick KM, Russell LL, Paterson RW, Keshavan A, Fox NC, Warren JD, Schott JM, Zetterberg H, Rohrer JD
Alzheimer's research & therapy 2018 Aug 16;10(1):79
Alzheimer's research & therapy 2018 Aug 16;10(1):79
TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the Alzheimer's disease-associated H157Y variant.
Thornton P, Sevalle J, Deery MJ, Fraser G, Zhou Y, Ståhl S, Franssen EH, Dodd RB, Qamar S, Gomez Perez-Nievas B, Nicol LS, Eketjäll S, Revell J, Jones C, Billinton A, St George-Hyslop PH, Chessell I, Crowther DC
EMBO molecular medicine 2017 Oct;9(10):1366-1378
EMBO molecular medicine 2017 Oct;9(10):1366-1378
A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis.
Cooper-Knock J, Green C, Altschuler G, Wei W, Bury JJ, Heath PR, Wyles M, Gelsthorpe C, Highley JR, Lorente-Pons A, Beck T, Doyle K, Otero K, Traynor B, Kirby J, Shaw PJ, Hide W
Acta neuropathologica communications 2017 Mar 16;5(1):23
Acta neuropathologica communications 2017 Mar 16;5(1):23
A split-luciferase complementation, real-time reporting assay enables monitoring of the disease-associated transmembrane protein TREM2 in live cells.
Varnum MM, Clayton KA, Yoshii-Kitahara A, Yonemoto G, Koro L, Ikezu S, Ikezu T
The Journal of biological chemistry 2017 Jun 23;292(25):10651-10663
The Journal of biological chemistry 2017 Jun 23;292(25):10651-10663
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- TREM-2 in Human PBMCs. TREM-2 was detected in immersion fixed human peripheral blood mononuclear cells (PBMCs) stimulated with LPS using Goat Anti-Human TREM-2 Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF1828) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Streptavidin (red; Catalog # NL999) and counterstained with DAPI(blue). Specific staining was localized to cytoplasm. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.
